Aquestive Therapeutics Earnings Estimate

AQST Stock  USD 3.10  0.01  0.32%   
The next projected EPS of Aquestive Therapeutics is estimated to be -0.105625 with future projections ranging from a low of -0.125 to a high of -0.0825. Aquestive Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.45. Please be aware that the consensus of earnings estimates for Aquestive Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Aquestive Therapeutics is projected to generate -0.105625 in earnings per share on the 31st of December 2024. Aquestive Therapeutics earnings estimates show analyst consensus about projected Aquestive Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Aquestive Therapeutics' historical volatility. Many public companies, such as Aquestive Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Aquestive Therapeutics Revenue Breakdown by Earning Segment

By analyzing Aquestive Therapeutics' earnings estimates, investors can diagnose different trends across Aquestive Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit Margin is likely to gain to 0.73 in 2025, whereas Gross Profit is likely to drop slightly above 31.9 M in 2025.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

Aquestive Therapeutics Earnings Estimation Breakdown

The calculation of Aquestive Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Aquestive Therapeutics is estimated to be -0.105625 with the future projection ranging from a low of -0.125 to a high of -0.0825. Please be aware that this consensus of annual earnings estimates for Aquestive Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.13
-0.12
Lowest
Expected EPS
-0.105625
-0.08
Highest

Aquestive Therapeutics Earnings Projection Consensus

Suppose the current estimates of Aquestive Therapeutics' value are higher than the current market price of the Aquestive Therapeutics stock. In this case, investors may conclude that Aquestive Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Aquestive Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
966.63%
-0.13
-0.105625
-0.45

Aquestive Therapeutics Earnings History

Earnings estimate consensus by Aquestive Therapeutics analysts from Wall Street is used by the market to judge Aquestive Therapeutics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Aquestive Therapeutics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Aquestive Therapeutics Quarterly Gross Profit

9.11 Million

Price Earnings To Growth Ratio is likely to gain to 0.17 in 2025, despite the fact that Retained Earnings are likely to grow to (272.8 M). Common Stock Shares Outstanding is likely to drop to about 37.4 M in 2025. Net Loss is likely to drop to about (51.4 M) in 2025.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aquestive Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.163.157.25
Details
Intrinsic
Valuation
LowRealHigh
0.905.009.10
Details
9 Analysts
Consensus
LowTargetHigh
9.8610.8312.02
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Aquestive assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Aquestive Therapeutics. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Aquestive Therapeutics' stock price in the short term.

Aquestive Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Aquestive Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Aquestive Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Aquestive Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Aquestive Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Aquestive Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Aquestive Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Aquestive Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Aquestive Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-04
2024-09-30-0.13-0.130.0
2024-08-06
2024-06-30-0.12-0.030.0975 
2024-05-07
2024-03-31-0.08-0.17-0.09112 
2024-03-05
2023-12-31-0.08-0.11-0.0337 
2023-11-06
2023-09-30-0.11-0.030.0872 
2023-08-07
2023-06-30-0.12-0.10.0216 
2023-05-02
2023-03-31-0.19-0.120.0736 
2023-03-07
2022-12-31-0.23-0.230.0
2022-11-01
2022-09-30-0.31-0.230.0825 
2022-08-02
2022-06-30-0.36-0.360.0
2022-05-03
2022-03-31-0.41-0.320.0921 
2022-03-08
2021-12-31-0.47-0.380.0919 
2021-11-02
2021-09-30-0.45-0.370.0817 
2021-08-03
2021-06-30-0.44-0.330.1125 
2021-05-04
2021-03-31-0.43-0.410.02
2021-03-09
2020-12-31-0.26-0.6-0.34130 
2020-11-04
2020-09-30-0.46-0.49-0.03
2020-08-04
2020-06-30-0.43-0.070.3683 
2020-05-05
2020-03-31-0.47-0.49-0.02
2020-03-11
2019-12-31-0.39-0.48-0.0923 
2019-11-05
2019-09-30-0.69-0.540.1521 
2019-08-06
2019-06-30-0.62-0.82-0.232 
2019-05-08
2019-03-31-0.5-0.59-0.0918 
2019-03-14
2018-12-31-0.51-0.56-0.05
2018-11-06
2018-09-30-0.43-0.64-0.2148 
2018-09-04
2018-06-30-0.24-1.9-1.66691 
2018-04-11
2018-03-310-0.47-0.47
2007-08-29
2007-06-300-0.25-0.25

About Aquestive Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Aquestive Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Aquestive Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Aquestive Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-287.2 M-272.8 M
Retained Earnings Total Equity-231.1 M-242.7 M
Earnings Yield(0.07)(0.08)
Price Earnings Ratio(14.15)(14.86)
Price Earnings To Growth Ratio 0.16  0.17 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.